Celyad (CYAD) Getting Favorable Press Coverage, Analysis Shows

Media coverage about Celyad (NASDAQ:CYAD) has trended positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celyad earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.7045478605005 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:CYAD opened at $30.93 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.58 and a quick ratio of 4.58. Celyad has a 1 year low of $28.29 and a 1 year high of $64.75. The stock has a market cap of $310.98, a PE ratio of -8.74 and a beta of 1.61.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/18/celyad-cyad-getting-favorable-press-coverage-analysis-shows.html.

Celyad Company Profile

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply